A Phase 1/2a - Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects With Chronic Hepatitis B Infection, Including Subjects With Chronic Hepatitis D Infection